Subcutaneous Isatuximab Improved Patient Comfort
Patients with multiple myeloma reported less pain and higher satisfaction with at-home injections than intravenous infusions.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Do you believe at-home administration options make managing chronic health conditions easier for patients?
Data from the phase 3 IRAKLIA trial revealed that patients receiving subcutaneous isatuximab preferred the method over traditional intravenous delivery. This study, which analyzed results from 531 participants, suggests that on-body injectors could offer a more convenient alternative for those undergoing treatment.
Why it matters
The findings highlight a shift in treatment delivery that prioritizes patient comfort and potentially reduces the burden of clinic visits for people managing relapsed or refractory multiple myeloma. By enabling self-administration, this method could change how patients balance long-term therapy with their daily lives.
In a phase 3 randomized trial of 531 patients with relapsed/refractory multiple myeloma, the overall response rate was 71.1% for the subcutaneous arm compared to 70.5% for the intravenous arm. The findings confirm clinical non-inferiority while measuring patient-reported outcomes.
The players
International Myeloma Society
A global scientific organization dedicated to advancing research and clinical care for plasma cell disorders.
U.S. Food and Drug Administration
The federal agency responsible for evaluating the safety and efficacy of pharmaceutical products in the United States.
The details
The subcutaneous formulation uses an on-body injector to deliver a fixed 1400-mg dose of isatuximab. Compared to the weight-based 10 mg/kg intravenous infusion, the on-body device allows for shorter administration times and greater independence. Trial participants reported significantly less discomfort and pain with the subcutaneous injector, with a 100% completion rate observed during the at-home substudy of 148 injections.
Timeline
July 2026: The FDA approved the subcutaneous isatuximab formulation.
September 23-26, 2026: Results were presented at the 23rd International Myeloma Society Annual Meeting in Glasgow.
Health Landscape
The transition toward subcutaneous delivery reflects a broader effort in oncology to move complex treatments from the infusion chair into the patient's home. This shift complements ongoing research into patient-reported convenience as a key metric for long-term treatment adherence.
Patients currently on infusion-based therapies for multiple myeloma may wish to discuss the availability of subcutaneous delivery methods with their oncologist. Understanding whether your specific treatment plan allows for home-based on-body injectors could help improve your comfort during care.
The takeaway
The IRAKLIA trial suggests that subcutaneous drug delivery can maintain clinical efficacy while significantly improving patient comfort compared to intravenous infusions. Patients should consult their care team about whether updated delivery methods are appropriate for their current treatment regimen.
Further reading
Learn more about the latest innovations in Cancer treatment and research.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Do you believe at-home administration options make managing chronic health conditions easier for patients?
